產品
Amgen-AstraZeneca's Tezspire nets another Phase III inflammatory disease win
Tezspire, co-developed by AstraZeneca and Amgen, hit its endpoints in a Phase 3 trial in eosinophilic esophagitis, opening a potential new indication.
大盤 開啟原文 ↗
重要性是模型對已發布報導給出的 1–5 分,不是對市場的預測。
已排定事件列上的影響是公司顯著度層級(高/中由圖譜中心度與規模判定;低僅用於人工整理的次要事件),不是對波動幅度的預測。
標記為已確認的財報日期,是 Yahoo Finance 認定由公司確認的;預估表示尚未公布。未加標記的列沒有可查的出處記錄。
經濟數據發布屬於總體經濟、不歸屬任何產業,因此在任何檢視下都會保留。沒有數值的發布表示尚未公布,頁面會直說,而不是顯示為零。
涵蓋被追蹤公司的即將到來的事件;已過去的事件會歸檔,並在可得時補上結果——這些結果都經人工整理並附引用,絕不杜撰。沒有結果的歷史列會顯示「結果待定」。
閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數,或指數基金必須買進的股數,以佔流通股的比例表示——依招股說明書或指數編製方法讀出,兩個數字都在該列註明出處。它陳述的是機制,不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估,直到公司自己說明為止。
10月22日週四 · 今天
8月27日週四
產品
Tezspire, co-developed by AstraZeneca and Amgen, hit its endpoints in a Phase 3 trial in eosinophilic esophagitis, opening a potential new indication.
大盤 開啟原文 ↗
8月26日週三
財報
Yahoo Finance reports NVIDIA's fiscal Q2 results, characterising them as strong and driven by continued AI demand. No revenue, EPS or guidance figures are stated in the cited item, so none are recorded here.
Nvidia reports impressive Q2 earnings as AI boom rolls on Yahoo Finance Video and Josh Lipton Thu, August 27, 2026 at 6:33 AM GMT+10 NVDA AMZN GOOGL Nvidia ( NVDA ) reported another strong earnings report on Wednesday after the closing bell. Adjusted earnings per share (EPS) came in at $2.22 (compared to analyst estimates of $2.09), and revenue came in at $96.2B billion (compared to analyst estimates of $92.38 billion). Yahoo Finance's Josh Lipton and Breaking Business News Reporter Jake Conley take a closer look at the breaking numbers. Video Transcript 00:00 Speaker A Nvidia second quarter r…
產品
Boeing and RTX won a combined $766 million in B-52 modernization contracts, and Northrop Grumman received an award tied to a deep space radar program. The report does not break out individual dollar amounts per contractor.
大盤 開啟原文 ↗
合作
Amgen is ending a research partnership in Crohn's disease. The supplied text does not name the counterparty or the terms.
大盤 開啟原文 ↗
產品
Roche received FDA approval for companion diagnostic tests used to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma who are eligible for ZIIHERA.
大盤 開啟原文 ↗